首頁 > 市場調查報告書 > 製藥

生物製劑分子標靶治療學

單株抗體市場規模、佔有率和成長分析（按來源、適應症、生產類型、應用、給藥途徑、最終用途和地區分類）－2026-2033年產業預測

市場調查報告書

商品編碼

1897250

單株抗體市場規模、佔有率和成長分析（按來源、適應症、生產類型、應用、給藥途徑、最終用途和地區分類）－2026-2033年產業預測

Monoclonal Antibodies Market Size, Share, and Growth Analysis, By Source Type, By Indication, By Production Type, By Application, By Route of Administration, By End-Use, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月23日 | 出版商:

SkyQuest | 英文 211 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，全球單株抗體市場規模將達到 2,352.7 億美元，到 2025 年將達到 2,623.2 億美元，到 2033 年將達到 6,266.6 億美元，預測期（2026-2033 年）的複合年成長率為 11.5%。

生物製藥，尤其是單株抗體（mAb）的需求，主要受癌症、心血管疾病和自體免疫疾病等慢性疾病日益普遍的驅動。預計這一趨勢將推動單株抗體市場顯著成長。由於單株抗體已成為標靶治療的關鍵，並能有效中和病原體，因此逐漸獲得患者和醫療專業人員的認可。主要企業正積極研發促銷單株抗體療法。合作，例如致力於提高癌症治療效率和開發神經退化性疾病藥物的合作項目，對於開拓新的機會至關重要。這些努力正在推動單株抗體領域的發展，旨在擴大各種慢性疾病的治療選擇，並改善患者照護效果。

全球單株抗體市場促進因素

癌症和自體免疫疾病等慢性病的日益流行，正顯著推動全球單株抗體市場的成長。隨著人口老化和生活方式相關健康挑戰的增多，對標靶治療（尤其是單株抗體）的需求持續上升。這項轉變促使製藥公司加大對創新單株抗體療法研發的投入。精準醫療的日益普及進一步凸顯了對有效標靶治療的需求，促使各公司推動這一細分市場的發展，以滿足對先進治療方案日益成長的需求。

限制全球單株抗體市場的因素

全球單株抗體市場面臨的一大障礙是單株抗體研發和生產成本高。生產這些療法需要複雜而漫長的過程，包括昂貴的檢測和遵守監管標準，這些都導致了高昂的整體成本。這種經濟負擔會阻礙小型公司進入市場，並限制競爭和創新。此外，高昂的價格往往使患者無法獲得這些先進療法，這可能會阻礙整個單株抗體市場的擴張和潛力。這些因素共同構成了該產業成長面臨的重大挑戰。

全球單株抗體市場趨勢

全球單株抗體市場正經歷變革性趨勢：現有單株抗體專利到期推動生物相似藥的崛起。這項轉變使得更具成本效益的替代療法得以引入，既擴大了患者的用藥範圍，也提高了製藥公司的盈利。生物相似藥日益成長的市場接受度預計將改變市場動態，加劇單株抗體療法領域的競爭，並推動其進一步創新。這一趨勢不僅凸顯了治療方案可負擔性的重要性，也展現了透過更廣泛的治療選擇來改善患者預後的潛力。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

F. Hoffmann-La Roche Ltd（Switzerland）
Johnson & Johnson（USA）
Merck & Co., Inc.（USA）
AbbVie Inc.（USA）
Amgen Inc.（USA）
Novartis AG（Switzerland）
Bristol Myers Squibb Company（USA）
Eli Lilly and Company（USA）
Regeneron Pharmaceuticals Inc.（USA）
Biogen Inc.（USA）
UCB SA（Belgium）
Takeda Pharmaceutical Company Limited（Japan）
AstraZeneca PLC（UK）
GlaxoSmithKline plc（GSK）（UK）
Bayer AG（Germany）
Daiichi Sankyo Company, Limited（Japan）
Boehringer Ingelheim International GmbH（Germany）
Y-mAbs Therapeutics Inc.（USA）
Teva Pharmaceutical Industries Ltd.（Israel）

結論與建議

簡介目錄

Product Code: SQMIG35H2248

Global Monoclonal Antibodies Market size was valued at USD 235.27 Billion in 2024 and is poised to grow from USD 262.32 Billion in 2025 to USD 626.66 Billion by 2033, growing at a CAGR of 11.5% during the forecast period (2026-2033).

The demand for biologics, particularly monoclonal antibodies (mAbs), is significantly driven by the increasing prevalence of chronic diseases such as cancer, cardiovascular issues, and autoimmune disorders. Consequently, this trend positions the Monoclonal Antibodies Market for substantial growth. Awareness among patients and healthcare professionals is rising as mAbs become integral in targeted treatments, effectively neutralizing disease-causing agents. Leading companies within the industry are actively engaged in advancing and marketing mAb therapies. Collaborative efforts, such as partnerships focused on enhancing production for cancer treatment and developing drugs for neurodegenerative diseases, are pivotal in unlocking new opportunities. These initiatives are geared toward enhancing treatment options and improving patient care outcomes for a wide array of chronic conditions, thereby driving the mAbs sector forward.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Monoclonal Antibodies market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Monoclonal Antibodies Market Segments Analysis

Global Monoclonal Antibodies Market is segmented by Source Type, Indication, Production Type, Application, Route of Administration, End-Use and region. Based on Source Type, the market is segmented into Murine, Chimeric, Humanized, Human and Others. Based on Indication, the market is segmented into Cancer, Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases and Others. Based on Production Type, the market is segmented into In Vivo and In Vitro. Based on Application, the market is segmented intoOncology, Autoimmune Diseases, Infectious Diseases, Neurological Diseases and Others. Based on Route of Administration, the market is segmented into Intravenous, Subcutaneous, Intravitreal and Others. Based on End-Use, the market is segmented into Hospitals, Specialty Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Monoclonal Antibodies Market

The escalating prevalence of chronic diseases like cancer and autoimmune disorders significantly fuels the growth of the Global Monoclonal Antibodies market. As populations age and lifestyle-related health challenges become more common, the demand for targeted therapies, particularly monoclonal antibodies, continues to rise. This shift has prompted pharmaceutical companies to invest heavily in the research and development of innovative monoclonal antibody-based treatments. The increasing focus on precision medicine further amplifies the need for effective targeted therapies, driving advancements in this market segment as companies seek to meet the growing demand for advanced treatment options.

Restraints in the Global Monoclonal Antibodies Market

A significant barrier in the Global Monoclonal Antibodies market is the substantial cost associated with the development and production of monoclonal antibodies. The complex and lengthy processes required to produce these therapies, which include expensive testing and adherence to regulatory standards, contribute to high overall expenses. These financial burdens can deter smaller companies from entering the market, limiting competition and innovation. Additionally, the high prices often restrict patient access to these advanced treatments, which could hinder the overall expansion and potential of the Monoclonal Antibodies market. This combination of factors presents a notable challenge for growth in the sector.

Market Trends of the Global Monoclonal Antibodies Market

The Global Monoclonal Antibodies market is witnessing a transformative trend with the rise of biosimilars, driven by the expiration of patents on established monoclonal antibodies. This shift enables the introduction of cost-effective alternatives, facilitating broader access for patients while enhancing profitability for pharmaceutical companies. As biosimilars gain acceptance, the market dynamics are expected to evolve, fostering increased competition and stimulating further innovation in the development of monoclonal therapies. This trend not only underscores the importance of affordability in treatment options but also highlights the potential for enhanced patient outcomes through a wider array of therapeutic choices.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Monoclonal Antibodies Market Size by Source Type & CAGR (2026-2033)

Market Overview
Murine
Chimeric
Humanized
Human
Others

Global Monoclonal Antibodies Market Size by Indication & CAGR (2026-2033)

Market Overview
Cancer
- Breast cancer
- Colorectal cancer
- Lung cancer
- Ovarian cancer
- Others
Autoimmune Diseases
Inflammatory Diseases
Infectious Diseases
Others

Global Monoclonal Antibodies Market Size by Production Type & CAGR (2026-2033)

Market Overview
In Vivo
In Vitro

Global Monoclonal Antibodies Market Size by Application & CAGR (2026-2033)

Market Overview
Oncology
Autoimmune Diseases
Infectious Diseases
Neurological Diseases
Others

Global Monoclonal Antibodies Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Intravenous
Subcutaneous
Intravitreal
Others

Global Monoclonal Antibodies Market Size by End-Use & CAGR (2026-2033)

Market Overview
Hospitals
Specialty Centers
Others

Global Monoclonal Antibodies Market Size & CAGR (2026-2033)

North America (Source Type, Indication, Production Type, Application, Route of Administration, End-Use)
- US
- Canada
Europe (Source Type, Indication, Production Type, Application, Route of Administration, End-Use)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Source Type, Indication, Production Type, Application, Route of Administration, End-Use)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Source Type, Indication, Production Type, Application, Route of Administration, End-Use)
- Brazil
- Rest of Latin America
Middle East & Africa (Source Type, Indication, Production Type, Application, Route of Administration, End-Use)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

F. Hoffmann-La Roche Ltd (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
UCB S.A. (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (GSK) (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Daiichi Sankyo Company, Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim International GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Y-mAbs Therapeutics Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments